Literature DB >> 24790144

Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice.

Marco Macagno1, Silvio Bandini1, Lorenzo Stramucci2, Elena Quaglino1, Laura Conti1, Elisa Balmas1, Mark J Smyth3, Pier-Luigi Lollini4, Piero Musiani2, Guido Forni1, Manuela Iezzi2, Federica Cavallo5.   

Abstract

Perforin (pfp)-mediated cytotoxicity is one of the principal immunosurveillance mechanisms involved in the fight against cancer. However, its importance in spontaneous epithelial cancer is still poorly defined. In this study, we use a realistic mouse model that displays many features that are equivalent to human pathology to evaluate the role of pfp-dependent immunosurveillance by comparing tumor progression in rat ERBB-2 (neu) transgenic, pfp-proficient (neu(+)/pfp(+)) or pfp-deficient (neu(+)/pfp(-)) BALB/c male mice. Adult neu(+)/pfp(+) males developed poorly differentiated salivary carcinomas, whereas neu(+)/pfp(-) males displayed their salivary carcinomas noticeably earlier and showed zones of more highly differentiated tumor, indicating that pfp-mediated immunosurveillance is able not only to delay the growth kinetic of an aggressive epithelial tumor, but also to shape its histology. The role of pfp-mediated immunosurveillance appeared to be of even more dramatic importance against the less aggressive male mammary carcinomas. In neu(+)/pfp(+) males, the incidence of mammary carcinomas was a sporadic and late event. In contrast, in neu(+)/pfp(-) males their incidence was four-fold higher. This higher cancer incidence was associated with a 2-fold higher occurrence of persisting mammary remnants, a major risk factor for mammary cancer in male mice, and one that would appear to be due to pfp's previously unidentified involvement in male mammary gland rejection during embryogenesis. This work thus provides further proof of the complex role that the immune system plays in the body and gives new insight into the pathogenesis of epithelial tumors, demonstrating that the penetrance and malignancy of a tumor may be dramatically affected by pfp-dependent mechanisms.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24790144     DOI: 10.4049/jimmunol.1301248

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  NK cells control breast cancer and related cancer stem cell hematological spread.

Authors:  Rossana Tallerico; Laura Conti; Stefania Lanzardo; Rosa Sottile; Cinzia Garofalo; Arnika K Wagner; Maria H Johansson; Costanza Maria Cristiani; Klas Kärre; Ennio Carbone; Federica Cavallo
Journal:  Oncoimmunology       Date:  2017-02-23       Impact factor: 8.110

Review 2.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

3.  Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis.

Authors:  Emilie T E Gross; Semi Han; Prasantha Vemu; Carlos D Peinado; Martin Marsala; Lesley G Ellies; Jack D Bui
Journal:  Oncoimmunology       Date:  2016-12-14       Impact factor: 8.110

4.  Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells.

Authors:  Gaetano Donofrio; Giulia Tebaldi; Stefania Lanzardo; Roberto Ruiu; Elisabetta Bolli; Andrea Ballatore; Valeria Rolih; Francesca Macchi; Laura Conti; Federica Cavallo
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

5.  The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.

Authors:  Silvio Bandini; Marco Macagno; Albana Hysi; Stefania Lanzardo; Laura Conti; Amanda Bello; Federica Riccardo; Roberto Ruiu; Irene Fiore Merighi; Guido Forni; Manuela Iezzi; Elena Quaglino; Federica Cavallo
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

6.  Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy.

Authors:  Antonino Di Lorenzo; Elisabetta Bolli; Roberto Ruiu; Giuseppe Ferrauto; Enza Di Gregorio; Lidia Avalle; Aurora Savino; Pietro Poggio; Irene Fiore Merighi; Federica Riccardo; Mara Brancaccio; Elena Quaglino; Federica Cavallo; Laura Conti
Journal:  Oncoimmunology       Date:  2022-06-15       Impact factor: 7.723

7.  Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Authors:  Stefania Croci; Patrizia Nanni; Arianna Palladini; Giordano Nicoletti; Valentina Grosso; Giorgia Benegiamo; Lorena Landuzzi; Alessia Lamolinara; Marianna L Ianzano; Dario Ranieri; Massimiliano Dall'Ora; Manuela Iezzi; Carla De Giovanni; Pier-Luigi Lollini
Journal:  Breast Cancer Res       Date:  2015-05-22       Impact factor: 6.466

Review 8.  Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.

Authors:  Laura Conti; Roberto Ruiu; Giuseppina Barutello; Marco Macagno; Silvio Bandini; Federica Cavallo; Stefania Lanzardo
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

9.  A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo.

Authors:  Elisabetta Bolli; John P O'Rourke; Laura Conti; Stefania Lanzardo; Valeria Rolih; Jayne M Christen; Giuseppina Barutello; Marco Forni; Federica Pericle; Federica Cavallo
Journal:  Oncoimmunology       Date:  2017-12-06       Impact factor: 8.110

10.  The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis.

Authors:  Federica Fusella; Laura Seclì; Elena Busso; Anna Krepelova; Enrico Moiso; Stefania Rocca; Laura Conti; Laura Annaratone; Cristina Rubinetto; Maurizia Mello-Grand; Vijay Singh; Giovanna Chiorino; Lorenzo Silengo; Fiorella Altruda; Emilia Turco; Alessandro Morotti; Salvatore Oliviero; Isabella Castellano; Federica Cavallo; Paolo Provero; Guido Tarone; Mara Brancaccio
Journal:  Nat Commun       Date:  2017-11-21       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.